[{"address1": "675 Massachusetts Avenue", "address2": "14th Floor", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "857 242 1600", "website": "https://sperotherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 46, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ankit  Mahadevia M.D., MBA", "age": 42, "title": "Co-Founder & Chairman of the Board", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 1385907, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Satyavrat  Shukla C.F.A.", "age": 50, "title": "President, CEO & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1120328, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy  Keutzer", "age": 55, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 938570, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther P. Rajavelu", "age": 44, "title": "CFO, Chief Business Officer & Treasurer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James P. Brady", "title": "Chief Human Resource Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kamal  Hamed M.B.A., M.D., M.P.H.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.31, "open": 1.32, "dayLow": 1.31, "dayHigh": 1.34, "regularMarketPreviousClose": 1.31, "regularMarketOpen": 1.32, "regularMarketDayLow": 1.31, "regularMarketDayHigh": 1.34, "beta": 0.624, "trailingPE": 3.9117649, "forwardPE": -1.0, "volume": 97485, "regularMarketVolume": 97485, "averageVolume": 135198, "averageVolume10days": 132000, "averageDailyVolume10Day": 132000, "bid": 1.32, "ask": 1.35, "bidSize": 400, "askSize": 400, "marketCap": 71885304, "fiftyTwoWeekLow": 0.99, "fiftyTwoWeekHigh": 1.89, "priceToSalesTrailing12Months": 0.606837, "fiftyDayAverage": 1.3435, "twoHundredDayAverage": 1.4539, "currency": "USD", "enterpriseValue": 12215372, "profitMargins": 0.14735, "floatShares": 40465509, "sharesOutstanding": 54049100, "sharesShort": 376738, "sharesShortPriorMonth": 390337, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0069999998, "heldPercentInsiders": 0.20382999, "heldPercentInstitutions": 0.26112, "shortRatio": 3.45, "shortPercentOfFloat": 0.0085, "bookValue": 1.49, "priceToBook": 0.89261746, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 17455000, "trailingEps": 0.34, "forwardEps": -1.33, "pegRatio": -0.03, "enterpriseToRevenue": 0.103, "enterpriseToEbitda": 0.581, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SPRO", "underlyingSymbol": "SPRO", "shortName": "Spero Therapeutics, Inc.", "longName": "Spero Therapeutics, Inc.", "firstTradeDateEpochUtc": 1509629400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0fee7cf4-78a9-330e-9cc6-7ef5c705eb66", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.33, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 63527000, "totalCashPerShare": 1.175, "ebitda": 21008000, "totalDebt": 4938000, "quickRatio": 2.608, "currentRatio": 2.678, "totalRevenue": 118459000, "debtToEquity": 6.134, "revenuePerShare": 2.223, "returnOnAssets": 0.104820006, "returnOnEquity": 0.25805, "freeCashflow": 1475500, "operatingCashflow": -14384000, "revenueGrowth": 2.754, "grossMargins": 0.37523997, "ebitdaMargins": 0.17733999, "operatingMargins": -1.86928, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]